Alta Natural: Hepatico Results In; Hepatitis-C
Sufferers Benefit from Naturopathic Treatment
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--Oct. 19, 1998--
Alta Natural Herbs(Alberta Stock Exchange:AHS.) Company President,
Adolf Huckschlag, reports that preliminary test data has been
received that indicates The Company's Hepatitis-C treatment,
Hepatico, is having a positive effect on sufferers in their test
group. "We are seeing a reduction of fatigue and nausea,
normalization of digestive functions as well as improvements in
sleeping and eating habits." According to Dr. David Khoupenia, Alta
Natural's study coordinator.
The data, which represents a 60-day or less treatment regimen
for the study participants, indicates statistically significant
reductions in ALT and AST liver enzyme measurements. Although the
results have not been fully compiled and published, enzyme
reduction over the 60 day period range from 0 percent to 78 percent
with most patients experiencing reductions.
"These results," said Khoupenia, "although not conclusive at
this point, when interpreted in light of favourable physical
improvements noted by a majority of sufferers, indicate that
Hepatico may be highly beneficial to those suffering from this
fatal disease."
These results are the first to be received from this nine-month
study of the efficacy of Hepatico in alleviating the suffering and
debilitating symptoms associated with infection from the
Hepatitis-C virus. There are currently few effective options for
the 170,000,000 people suffering from Hep- C. Unlike Hepatico which
is atoxic, most effective drug-based treatments are highly toxic
and can be extremely debilitating, to the point of causing death in
some patients.
The Company will release detailed preliminary results as soon as
they are available. This is the final step in The Company's
assessment of the healing value and market potential of this
naturopathic treatment. The Company is also in possession of 17
clinical and pre-clinical trials conducted in Europe on Hepatico
between 1992 and 1996. The conclusions of those studies will be
compared with these preliminary in-house tests and an announcement
with respect to Alta Natural's plans for this treatment will be
made in two news conferences to be conducted in Canada and The
United States. The exact time and location of these announcements
will be determined within days.
The Alberta Stock Exchange has neither approved nor
disapproved of the contents of this release.
CONTACT: Alta Natural Herbs & Supplements Ltd.;Raymond J.
Irvine, 604/ 689-0087 or 1-800-969-7222
Website: www.alta-natural.com
Email: altanat@axionet.com
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|